WO2025243064 - THE PROCESS OF PRODUCING EXOSOMES CONTAINING MIR-299-5P FOR THE TREATMENT OF ALZHEIMER'S DISEASE
National phase entry is expected:
Publication Number
WO/2025/243064
Publication Date
27.11.2025
International Application No.
PCT/IB2024/054863
International Filing Date
19.05.2024
Title **
[English]
THE PROCESS OF PRODUCING EXOSOMES CONTAINING MIR-299-5P FOR THE TREATMENT OF ALZHEIMER'S DISEASE
[French]
PROCÉDÉ DE PRODUCTION D'EXOSOMES CONTENANT DU MIR-299-5P POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Applicants **
JAFARLOU, Mahdi
Inventors
JAFARLOU, Mahdi
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4179 | |
| EPO | Filing, Examination, Granting | 55967 | |
| Japan | Filing, Examination, Granting | 4493 | |
| South Korea | Filing, Examination, Granting | 6812 | |
| USA | Filing, Examination, Granting | 70140 |
Total:
141,591
Contact Us
Abstract[English]
The main problem with treating Alzheimer' s is that there is no certain medicine for its treatment, or that there is medical resistance to it in the patient's body. By using the WJ-MSCs exosomes from the steam cells grade, the exosomes are extracted with the ultracentrifuge method and confirmed in the size of SEM and TEM exosomes in the range of less than 100nm. then the mir-299-5p is transfected to the cell WJ- MSCs, with the help of a vector, and the exosomes are then extracted, gathered, and formulated. Since the vesicles are under 100 nanometers (exo som es) and could enter the cell by passing the brain blood barrier, what is inside them is easily transferred into the neuronic cell and treats them. Also, it decreases the drug resistance in the body, and the existence of the mir-299-5p is targeted, has pharmaceutical effects, and recovers the neuronic cells that were injured.[French]
Le principal problème lié au traitement de la maladie d'Alzheimer réside dans l'absence de médicament spécifique pour son traitement, ou dans la résistance médicale du corps du patient à ce traitement. Des exosomes WJ-MSC provenant de cellules souches sont extraits à l'aide d'un procédé d'ultracentrifugation, puis leur taille est confirmée par MEB et MET comme se situant dans une plage inférieure à 100 nm, puis un miR-299-5p est transfecté dans les cellules WJ-MSC à l'aide d'un vecteur, et les exosomes sont ensuite extraits, collectés et formulés. Comme les vésicules mesurent moins de 100 nanomètres (exosomes) et sont susceptibles de pénétrer dans la cellule en franchissant la barrière hématoencéphalique, leur contenu est facilement transféré dans la cellule neuronale pour y être traité. De plus, la résistance aux médicaments dans l'organisme diminue, et la présence du miR-299-5p est ciblée, produit des effets pharmaceutiques, et permet la régénération des cellules neuronales endommagées.